Heavyweight News in Heart Failure Treatment Track! Innovate Medical Device Company Headquartered in New Jersey, USAImpulse Dynamics recently completed a financing round exceeding $158 million,Triggered high attention in the industry. This funding will fully advance its coreCardiac Contractility Modulation (CCM) TherapyThe commercialization process, while intensifying clinical research and technological iteration, injects new vitality into the field of heart failure treatment.

From the lineup of investors, this round of financing is highly noteworthy: it not only attracted strong participation from new institutional investors such as Sands Capital and Braidwell, but also saw continued investment from existing shareholders like Redmile, Perceptive, and Alger. This fully demonstrates the capital market's firm confidence in the clinical value and commercialization prospects of CCM therapy.

1. What is CCM Therapy?

Cardiac Contractility Modulation (CCM) is an innovative heart failure treatment technology that enhances myocardial contractility and improves cardiac function by delivering electrical stimulation during specific periods of the cardiac cycle via an implantable medical device, without affecting the heart rhythm.

2. Working Principle: "Cardiac Strengthening without Rhythm Adjustment"

The core mechanism of CCM is inAbsolute Refractory Period of Cardiac Muscle Cell Action Potential(i.e., the brief period after the heart just contracts during which it does not respond to new stimuli, approximately within 30ms after the R wave) releaseHigh-Voltage Biphasic Electrical Pulse(7.5V, 5-20ms pulse width). This unique timing stimulation does not trigger a new heartbeat, but can:

• Enhance calcium ion influx, improve calcium homeostasis in cardiomyocytes
• Promote calcium ion release from the sarcoplasmic reticulum and enhance the sensitivity of contractile proteins to calcium.
• Activate Key Protein Phosphorylation, Enhance Myocardial Contractility
• Reverse myocardial fibrosis and improve cardiac remodeling
• Regulate autonomic nerve balance, reduce myocardial oxygen consumption

Key Differences: Unlike traditional pacemakers, CCM does not alter the heart's rhythm but enhances the contractile strength of each heartbeat, akin to installing a "power booster" for a "fatigued heart."

III. Indications: A "Cardiac Strengthening Solution" with Precision Matching

CCM is suitable for patients with specific types of heart failure:

Special Advantages: Fills approximately 65%-70%Narrow QRS Heart Failure Patients(Not suitable for CRT) device treatment gap.

4. Treatment Process: Minimally Invasive Surgery, Long-Lasting "Heart Strengthening"

1. Implantation Surgery (Approximately 1-2 Hours)

• Performed under local anesthesia, similar to pacemaker implantation.
• ThroughSubclavian VeinOrFemoral VeinPuncture, place the electrode lead inRight Ventricular Septum
• The pulse generator is implanted subcutaneously below the clavicle.
• Intraoperative testing ensures stimulation effect without affecting normal cardiac rhythm.

2. Postoperative Use

• Device PassedExternal ChargerWireless charging, battery life approximately 3-5 years
• Approximately every day5-Hour Treatment(Usually divided into 5 sessions, each lasting 1 hour)
• Doctors adjust parameters through a programmer to ensure optimal results.

5. Clinical Effect: Changing Lives from the "Heart"

Multiple international clinical trials have confirmed that CCM can significantly improve:

• Cardiac Function
  LVEF increased by approximately 5-10%, and cardiac output increased by 15-20%.
• Exercise Tolerance
  6-minute walking distance increased by 40-60 meters, improving shortness of breath
• Quality of Life
  Minnesota Heart Failure Quality of Life Questionnaire Score Increase by 20-30 Points
• Hospitalization Risk
  Heart Failure Readmission Rate Reduced by 30-50%
• Long-term Survival
  Two-year survival rate reached 86.4%, significantly better than expected

Real Cases: A 73-year-old patient regained the ability to walk freely after surgery, with cardiac systolic function improving from 28% to 32%, and the left ventricle shrinking from 82mm to 73mm.

6. Safety and Risk

• Overall safety is good, with a serious complication rate < 5%.
• Common Mild Discomfort: Temporary chest pain or muscle twitching (can be alleviated by adjusting parameters)
• No Risk of Arrhythmia (Stimulation Occurs During the Refractory Period)
• Without affecting the normal electrical activity and rhythm of the heart

7. Differences from other heart failure treatments

Key Advantages: CCM fills the treatment gap for heart failure patients with narrow QRS who cannot be covered by traditional CRT, offering new hope to these patients in "therapeutic dilemma."

8. Combination Therapy: "Strong Alliance" for Better Results

• CCM + Medication
  Synergistic effect, enhanced efficacy, significant improvement in cardiac function and quality of life, reduced risk of rehospitalization
• CCM+ICD
  One-stop Solution for "Myocardial Contraction Weakness + Malignant Arrhythmia" Dual Risks Successfully Implemented in Multiple Hospitals
• CCM+CRT Non-Responding Patients
  Provide "Second-Chance Therapy" Options for Patients with Poor CRT Outcomes

Cardiac Contractility Modulation (CCM) therapy is a significant innovation in the field of heart failure treatment.It provides a new treatment option for heart failure patients with narrow QRS who do not respond well to medication and are not suitable for traditional CRT through its unique "cardiac strengthening without rhythm adjustment" mechanism. This technology can significantly improve cardiac function, enhance quality of life, and reduce the risk of hospitalization, rekindling hope for many heart failure patients.

Policy Tailwind Boost: CMS Coverage Expansion, CCM Therapy Sheds "Experimental" Label

This financing round is particularly critical, coming just after a major policy shift by the U.S. Centers for Medicare & Medicaid Services (CMS). Recently, CMS issued a National Coverage Determination for CCM therapy, expanding its coverage to over 66 million beneficiaries and including it as one of the few selected therapies in the 2025 "Transitional Coverage for Emerging Technologies" pathway.

This policy adjustment is of far-reaching significance – it means that CCM therapy has officially shed its label as an "experimental or investigational treatment" and become a compliant clinical treatment option, marking a qualitative leap in the accessibility of heart failure treatment in the United States. It also clears a key payment barrier for Impulse Dynamics’ commercial expansion.

Filling the Clinical Gap: CCM Therapy Breaks the "Dilemma" in Heart Failure Treatment

"This financing reflects the growing confidence in the market regarding the company's progress and clinical evidence," said Jason Spees, CEO of Impulse Dynamics. "This support acknowledges the evidence-based efficacy of CCM therapy – to date, more than 12,000 patients have received implants, opening the door for more heart failure patients to receive treatment."

He further revealed that the new funds will focus on accelerating the development of the CCM-D HF system. This system innovatively integrates CCM therapy with implantable cardioverter-defibrillator (ICD) functionality into a single device, offering the potential to achieve the dual value of "enhanced efficacy + risk protection."

Chairman of the Board Guido Neels pointed out the core competitiveness of CCM therapy: "Many patients continue to experience symptoms after receiving standard treatment. Impulse Dynamics uniquely fills a critical gap in heart failure treatment—providing symptom relief for patients with very limited treatment options beyond medication." The accumulating clinical evidence also lays a solid foundation for subsequent device innovation.

Focus on Core Trials: Tackling Treatment Challenges like Diastolic Heart Failure

This round of financing will focus on supporting the advancement of two key clinical trials: the multicenter INTEGRA-D trial, targeting heart failure patients who have received implantable defibrillators but still experience persistent symptoms, to evaluate the application effects of the CCM-D HF system; and the AIM HIGHer trial, specifically exploring the efficacy of CCM therapy in patients with diastolic heart failure.

Notably, patients with diastolic heart failure account for approximately half of all heart failure cases, and currently, treatment options are extremely limited. However, CCM therapy has been approved in Europe for such patients, and this trial is expected to bring new hope for these patients globally.

As the core carrier of CCM therapy, Optimizer, the flagship product of Impulse Dynamics, has accumulated substantial clinical evidence—its clinical performance and long-term efficacy are supported by more than 100 peer-reviewed publications, including several randomized controlled trials, providing strong support for the widespread application of the technology.